When an infection strikes a bone, a joint replacement or a surgical implant, the standard response has long been a long course of antibiotics — often many weeks. New trial data suggest that in many cases, a much shorter course may work just as well, with fewer side effects. It’s a potentially important shift in a field where “longer” has been the cautious default.

The problem with long courses

Orthopedic infections — involving implants, prosthetic joints or infected bone — are serious and hard to clear, so doctors have traditionally erred toward prolonged antibiotics to avoid relapse. But long courses come with costs: more side effects, disruption to the gut microbiome, the burden of extended treatment, and pressure toward antibiotic resistance. The open question has been whether all that duration is actually necessary once the infection has been surgically addressed.

What the trial tested

The SALATIO trials are randomized studies directly comparing shorter versus longer antibiotic courses after surgery for orthopedic infections. They split patients into groups: SALATIO 1 randomized people with infected implants (kept in place after cleaning out the infection) to a short 6-week versus a long 12-week course; SALATIO 2 randomized people undergoing implant removal or a two-stage exchange to a short 3-week versus long 6-week course. In each case, the shorter arm is half the traditional duration.

The interim findings

A second interim analysis found no disadvantage from the shorter regimens: outcomes in the short-course groups held up against the longer ones, while adverse events were reduced. In the language of clinical trials, the shorter courses are looking non-inferior — just as good on what matters — while being easier on patients. That combination is exactly what stewardship-minded clinicians hope for.

Why it matters

If confirmed, shorter courses would mean less antibiotic exposure for patients — fewer side effects, lower cost, less disruption — and a meaningful contribution to antimicrobial stewardship, the effort to use antibiotics only as much as necessary to slow the rise of resistant bacteria. It reflects a broader movement across medicine to right-size antibiotic durations, as trial after trial finds that many traditional courses were longer than they needed to be.

The caveats

Two cautions matter. First, these are interim results from ongoing trials — encouraging, but not the final word; the studies continue to full follow-up. Second, the findings apply to infections that have been surgically treated (with the infection source addressed and, in some arms, local antibiotics used), not to every bone infection — and individual decisions depend on the organism, the surgery and the patient. Treatment length should remain a clinical judgment, not a do-it-yourself calculation. This summarizes research and is not medical advice.